Compare SSP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSP | NGNE |
|---|---|---|
| Founded | 1878 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.7M | 327.8M |
| IPO Year | 1988 | N/A |
| Metric | SSP | NGNE |
|---|---|---|
| Price | $3.45 | $17.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.95 | ★ $40.14 |
| AVG Volume (30 Days) | ★ 491.4K | 145.7K |
| Earning Date | 02-25-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,318,706,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $6.88 |
| 52 Week High | $4.98 | $37.27 |
| Indicator | SSP | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 41.27 |
| Support Level | $3.30 | $18.12 |
| Resistance Level | $3.73 | $18.95 |
| Average True Range (ATR) | 0.18 | 1.34 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 27.62 | 16.23 |
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.